alimera.png
Alimera Sciences Proposes Public Offering of Common Stock
10 août 2016 16h01 HE | Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of...
Xtant™ Medical to Pr
Xtant™ Medical to Present at the Canaccord Genuity 2016 Musculoskeletal Conference
16 févr. 2016 07h30 HE | Xtant Medical Holdings, Inc.
BELGRADE, Mont., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading...
Xtant™ Medical To Pr
Xtant™ Medical To Present at ICV Manhattan Conference
03 déc. 2015 07h30 HE | Xtant Medical Holdings, Inc.
BELGRADE, Mont., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative...
Xtant Medical Holdin
Xtant Medical Holdings, Inc. Reports Third Quarter 2015 Results
11 nov. 2015 16h27 HE | Xtant Medical Holdings, Inc.
Third Quarter 2015 Consolidated Pro Forma Highlights: Consolidated pro forma revenue increased 6.5% to $20.9 million from $19.6 million in the third quarter of 2014. Excluding OEM revenue,...
Xtant Medical Announ
Xtant Medical Announces First Surgical Use of OsteoSelect® PLUS DBM Putty
03 nov. 2015 07h30 HE | Xtant Medical Holdings, Inc.
BELGRADE, Mont., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant Announces Prel
Xtant Announces Preliminary Third Quarter 2015 Revenue
13 oct. 2015 07h30 HE | Xtant Medical Holdings, Inc.
Third Quarter 2015 Pro Forma Combined Revenue in the range of $20.7 million to $20.9 million, an increase of 5.5 % to 6.5 % over the same period last yearExcluding OEM Revenue, Third Quarter 2015...